-
Gender Differences in the Economic Burden of Alcohol Use in Belgium
Sep 9, 2025, 16:22 PM -
What Generalized Cost-Effectiveness Analysis (GCEA) Reveals About the Applicability of Foreign Reference Pricing in Medicare Price Negotiation in the US
Sep 9, 2025, 16:22 PM -
Using Social Media Listening to Understand Oncology-Specific Patient Experiences: A Comparison of Pharmaceutical Industry-Funded vs. Nonpharmaceutical Industry-Funded Studies
Sep 9, 2025, 16:22 PM -
A Layered Approach to Reducing Hallucinations in LLMs for Structured and Unstructured Clinical Data
Sep 9, 2025, 16:22 PM -
Comorbidities and Comedication Among Individuals in Treatment for ADHD: A Danish Nationwide Study
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of the BCIS Conveyance Algorithm for Out-of-Hospital Cardiac Arrest Patients
Sep 9, 2025, 16:22 PM -
Clinical Outcome Assessments in Drug Approvals: Trends and Insights From FDA; EMA Labeling 2018-2023
Sep 9, 2025, 16:22 PM -
An Analysis of Possible Reference Countries for a US Most-Favored Nation Policy and the Associated Impact on the Global Pharmaceutical Industry
Sep 9, 2025, 16:22 PM -
Disability Resource Utilization and Caregiver Support Among a Real-World Sample of Patients With Transthyretin Amyloidosis With Polyneuropathy
Sep 9, 2025, 16:22 PM -
Clinical Utility of Multiplex Point of Care (PCR) Compared to Antigen Testing for Influenza-Like Illness in the Hospital Emergency Department
Sep 9, 2025, 16:22 PM -
Comparator Misalignment As a Contributor to Negative Reimbursement Decisions for Pharmaceuticals in Sweden
Sep 9, 2025, 16:22 PM -
Avacopan in the Treatment of ANCA-Associated Vasculitis: A Cost-Utility Analysis in Portugal
Sep 9, 2025, 16:22 PM -
Characterizing the UK Population Living With Von Willebrand Disease: Foundational Data for Health Economics and Outcomes Research
Sep 9, 2025, 16:22 PM -
Baseline Risk Heterogeneity in Cost-Effectiveness Analysis of the Diabetes Prevention Program
Sep 9, 2025, 16:22 PM -
Budget Impact of Nivolumab Plus Ipilimumab Plus Chemotherapy as First-Line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer in Switzerland
Sep 9, 2025, 16:22 PM -
Diverging Impacts of Evergreening and Biosimilars on Trastuzumab Utilization and Costs in South Korea: Implications for Sustainable Access and Market Competition
Sep 9, 2025, 16:22 PM -
Costing Analysis for the Management of Localized Renal Cell Carcinoma From the UK NHS Perspective
Sep 9, 2025, 16:22 PM -
Analysis of the Implementation of Additive PICOs in a European Joint Health Technology Assessment Implications of EUHTA for Pharma: A Qualitative Exploration
Sep 9, 2025, 16:22 PM -
KRAS Alterations in Advanced Non-Small Cell Lung Cancer (NSCLC): Temporal Trends in Testing Patterns and Targeted Treatment Use Across Europe Between 2018 and 2024
Sep 9, 2025, 16:22 PM -
Evaluating the Role of Societal Perspectives in the EU Joint Clinical Assessment Framework and in EU-27 Health Technology Assessment Guidelines
Sep 9, 2025, 16:22 PM
